Novartis said it returned to sales growth in the second quarter, as momentum from some of its key medicines and recent launches helped the company offset a hit from drugs that lost patent protection.

Novartis said it returned to sales growth for the second quarter, after lower-priced competition in the U.S. for drugs that went off patent weighed on its top and bottom lines in prior quarters. Net ...

Promacta (eltrombopag) can cause side effects ranging from mild issues like nausea and fatigue to more serious complications, such as cataracts. Promacta has boxed warnings about the potential for ...

The price for Doptelet oral tablets depends on several factors. These include your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help ...

Promacta (eltrombopag) is a brand-name drug prescribed for certain blood conditions. Promacta has interactions with some supplements and drugs. Examples include some antacids and certain statins. An ...

The company is recalling the lots because of possible peanut flour contamination. Novartis announced on May 11, 2019 that it was recalling three lots of Promacta (eltrombopag) 12.5 mg for oral ...

Novartis today announced a voluntary recall of three lots of Promacta (eltrombopag) 12.5 mg for oral suspension to the consumer level. The oral suspension lots are being recalled because of a risk of ...

Three lots of Promacta (eltrombopag; Novartis) for oral suspension 12.5mg are being recalled due to possible peanut flour contamination at a third-party manufacturer. Three lots of Promacta ...

Ligand Pharmaceuticals Incorporated LGND announced the sale of all rights to Novartis’ NVS blockbuster drug, Promacta (eltrombopag), to privately-held Royalty Phamra for $827 million. The sale also ...

SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Royalty Pharma announce the sale of Ligand’s Promacta ®-related intellectual property rights licensed to ...

When Novartis paid $16 billion to acquire GlaxoSmithKline’s cancer portfolio back in 2015, it picked up a few drugs that didn’t seem to have quite so clear growth prospects, including Promacta to ...